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Abstract Hepatocyte growth factor (HGF) is a protein produced by mesenchymal cells in many organs, which can
stimulate epithelial growth. An enhanced production and concentration of HGF is observed after injuries.The lung is
one of themajor sources of HGF.By cooling exhaled air, a condensate is formed containingmolecules frombronchi and
alveoli. In order to investigate HGFconcentration and time course inpneumonia, paired serumand exhaled breath con-
densate was collected from10 patients with pneumonia,10 patients with non-respiratory infections and11healthy con-
trols. The concentration of HGF was measured by an immunoassay kit. In the acute phase HGF-levels in breath
condensate and serumwere signi¢cantlyhigher in the patientswith pneumonia compared to the controlgroups.Similar
concentrations in breath condensatewere seen in healthycontrols and in patientswith non-respiratory infections.In the
patientswith pneumonia a decrease in serum HGF was seen already after 4^7 dayswhile HGF values in breath conden-
sate remained elevated even after 4^6 weeks.These resultsmight imply local production of HGF in the lungs and a long
repair andhealingprocess after pneumonia.r2001Elsevier Science Ltd
doi:10.1053/rmed.2001.1225, available online at http://www.idealibrary.comon
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Hepatocyte growth factor (HGF) is a heterodimeric
protein consisting of a 69 kDa a-subunit and a 34 kDa b-
subunit, linked together by a disulphidebond (1,2).HGF is
synthesized and secreted as a single chain precursor that
is cleavedand thereby activatedby a convertingprotease
(3).Thebiological functions ofHGF havebeenwidely stu-
died in recent years (4). After injuries, high amounts of
HGF are produced by mesenchymal cells and it is sup-
posed to play an important role in the regeneration of
epithelial cells in the injured organ (5^7). Increased ser-
um concentrations have been reported in infectious and
other general diseases. In the lungs HGF production by
¢broblasts andmacrophages promotes the proliferation
of type II epithelial cellswhich replace the destroyed cells
and thereby restore the integrity of the alveolar andReceived 4 September 2001accepted 25 September 2001, andpublished
online10 December 2001.
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HGF-mRNA in bronchial epithelial cells has already been
reported 3 h after induced lung injury in rats (5).Thus, an
increased local production might take place in pneumo-
nia. A new, simple method of collecting exhaled air has
recently been developed. Exhaled air containing the gas-
eous phase from the alveoli and micro-drops from the
bronchoalveolar lining £uid is cooled and water vapour
and water-soluble moleculesFeven with relatively high
molecular weightFcan be collected.This makes it pos-
sible to measure mediators carried by the exhaled air
and assess in£ammation in the lung (9). Most mediators
measured so far have been relatively small e.g. leuko-
trienes have been found in asthma (10). The presence of
HGF in exhaled breath condensate (EBC) has not been
investigated previously.The aim of the present investiga-
tion was to study the occurrence of HGF in breath con-
densate and investigate the relation between changes in
systemic and local concentrations of HGF during pneu-
monia. Therefore the interval paired serum and breath
condensate levels ofHGFweremeasuredinpatientswith
pneumonia and compared to a group of patients ad-
mitted to the hospital due to other infectious diseases
and to a healthy control group.
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Patients
Thirteen patients who were admitted to the Depart-
mentof InfectiousDiseases at LinkopingUniversityHos-
pital with a clinical picture and typical X-ray changes of
pneumonia were asked consecutively to join a prospec-
tive study. Ten patients (25^74 years, median 37 years
old) ful¢lled the study. Follow-up samples could not be
obtained in three patients (one was admitted to the
heart intensive care unit and two did not want to con-
tinue the study). Blood and nasopharynx cultures were
taken at the time of admittance to the hospital (data
not shown).Treatmentbegandirectly after cultureswere
taken. The patients were discharged and put on oral
treatment as soon as their temperature decreased and
they reached a stable circulatory and respiratory status.
Blood and exhaledbreath condensate for HGFmeasure-
ment were gathered within 24 h after admittance and
before the patient was discharged after 4^7 days as well
as after 4^6 weeks at a follow-up visit. The causes of
pneumonia (de¢ned by blood and nasopharynx cultures
and serologic tests) wereMycoplasma pneumoniae (n3)
Haemophilus in£uenza (n1), Streptococcus pneumonia
(n1) and unknown (n5).None of the patients su¡ered
from serious liver, kidney or chronic lung disease.
Controls
Two control groups were included in the study.The ¢rst
group consisted of11healthy vaccination volunteers (21^
73 years, median 31 years old) without any signs of cur-
rent infection. The second group comprised patients
(20^82 years, median 51years old) with a normal chest
X-ray who were admitted to the Department of Infec-
tiousDiseases for reasons other thanpneumonia.Thedi-
agnosis were: Lyme disease in one, infected ulcers of the
leg in two, urinary tract infection in one, fever of un-
known origin in two, erysipelas in one, gastroenteritis
in one, in£uenza in one and septic arthritis in the knee
in one patient. Paired blood and exhaled breath conden-
sate samples were gathered in both groups once and
stored as described below.
Collection of exhaled breath condensate
(EBC) and serum
Non-invasive collection of the non-gaseous part of ex-
haled cooled air was performed by using a condenser
(EcoScreen, Jaeger,Wˇrtsburg,Germany) equippedwith
a two-way non-re-breathing valve also functioning as a
saliva trap. Wearing a nose clip, patients and controls
were asked to breath normally for 10 min through the
unit.The condensateswereproducedatÿ201C,weighed
and immediately stored atÿ701C.The lowest amount ofcondensate produced was 0?1 gminÿ1 (mean value 0?16
gminÿ1).
Ten millilitres of venous blood was gathered and cen-
trifuged for 10 min at 1000 g within 1 h after vein punc-
ture, and serumwas stored atÿ701C.
Determination of HGF
Serum was thawed and centrifuged at 1000 g for 15 min
prior to analysis.
EBCwas thawed, a 500 ml portion of the sample was
freeze-dried and120 ml of distilled water was added be-
fore analysis.
Immunoreactive HGF was determined by the ELISA
technique, using a commercially available kit (Quantikine
HGF immunoassay, R&D systems Inc., Minneapolis,
U.S.A.).The lowest detectable amount by this assay was
0?04 ngmlÿ1.Doublemeasurementswere performed on
all samples, positive andnegative controlswere included,
and the absolutemethodological error forHGF in serum
was 0?076 and for HGF in breath condensatewas 0?058 .
Statistics
Thenatural logarithmof thevalueswas used for the ana-
lysis of HGF in serum and exhaled breath condensate.
Analysis of variance (ANOVA), followedbyDuncans test
in case of signi¢cance were used for statistical analysis
(STATISTICA).
RESULTS
The concentration of HGF in serum was higher in the
group of pneumonia patients in the acute phase (mean
2?53 ngmlÿ1) than in patientswith non-respiratory infec-
tions (mean 1?15 ngmlÿ1; Po0?0005) as well as the
healthy controls (mean 0?79 ngmlÿ1; Po0?0005). There
was a statistically signi¢cant decrease in the serum HGF
values during the treatment for pneumonia. Already at
days 4^7 the mean value for pneumonia patients was
1?31 ngmlÿ1 (Po0?003) and at convalescence (after 4^6
weeks) the mean value was 0?85 ngmlÿ1 (Po0?00005)
(Table1and Fig.1).Therewas no signi¢cantdi¡erence be-
tween serum concentrations of HGF in the pneumonia
group of patients at convalescence and the healthy con-
trol subjects.
HGF concentrations in exhaled breath condensate
were signi¢cantly higher during pneumonia (mean 0?18
ngmlÿ1; Po0?0005) compared to both the group with
non-respiratory infections and the healthy control sub-
jects (mean 0?047 and 0?064 ngmlÿ1, respectively) (Ta-
ble 1 and Fig. 1). In contrast to the serum ¢ndings, the
HGF levels in EBC did not decrease for the observation
period of 4^6 weeks after pneumonia (P40?9) (Fig. 2).
Therewas no signi¢cant correlation between HGF levels
TABLE 1. Measuredparameters and di¡erencesbetween groups
Ageyears
Median
Sex
(Female/
HGF (ngmlÿ1) mean7standard errorofthemean (SEM)
(range) male) HGF before treatment HGFafter treatment HGFatconvalescence
Serum Condensate Serum Condensate Serum Condensate
Pneumonia 37?5 (25^74) 8/2 2?5370?51 0?1870?03 1?3170?19 0?1570?02 0?8570?09 0?1770?03
Non-respiratory
infection
46 (20^82) 4/6 1?1570?16 0?04770?01
Healthycontrol 31 (21^3) 6/5 0?7970?10 0?06470?01
FIG. 1. Boxplot showingHGFlevels (naturallogarithmform) in
air condensate (hatched) and serum (open) in three included
groups (pneumonia; n10, non-respiratory infections; n10
andhealthycontrols; n11).
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material.
DISCUSSION
Hepatocyte growth factor (HGF) has been the focus of
several studies during the last decade. As one of its func-
tions it has been suggested that HGFmay act as a trigger
for regeneration in injured organs (1). High levels of ser-
umHGF during acute and chronic in£ammatory lung dis-
eases has been reported by Maeda et al. (11). However
few studies have investigated the role of HGF during the
course of infectious diseases (6).We have been studying
HGF in infectious diseases since 1996. Initially we ob-
served a positive correlation between low serum HGF
levels and high lactate dehydrogenase (LDH) with poor
prognosis in pneumonia (12). In a prospective study we
found that a rapid drop (in less than 48 h) in serum HGF
after therapy correlated with a successful outcome (un-
published data). All patients in this study were success-
fully treated and the raised serum HGF levels observed
in this study is consistent with previous ¢ndings. A drop
in serum values after successful treatment is also similarto what has been found in pneumonia (11) andmeningitis
(13).
Our aim was to study if a local production of HGF
couldbe detected in exhaled air condensate duringpneu-
monia and to follow its time course. A local production
could possibly be assessed by induced sputum or
bronchoscopy with lavage (BAL),methods noteasilyper-
formed on severely ill patients. The new method of col-
lecting exhaled air by cooling is easy on the patient and
allows sampling in spite of their symptoms. Exhaled air
contains the gaseous phase from the alveoli, water vapor
andmicro drops from the bronchoalveolar lining £uid. It
is probably in the small drops thatmost of the largermo-
lecules are carried and collected in the ice in the conden-
ser.The possibility to measure mediators carried by the
exhaled air and assess in£ammation in the lungs has re-
cently been reviewed (9). Most mediators measured so
far have a relatively small molecular weight e.g. leuko-
trienes or interleukins (10,14^16). The presence of HGF
in breath condensate has not been investigated pre-
viously.
Most methods for obtaining samples from the lung,
like sputum or BAL, are di⁄cult to standardize.Techni-
cally, the collection of exhaled breath condensate could
be subject to awide degree of error due to cooling e¡ec-
tiveness, breathing pattern (a higher ventilation might
give a greater production but a higher water content)
and other factors.Therefore all attempts were made to
minimize sources of error (using the same pattern
and person in collecting the samples and the same
ELISA batch). As a result the double measurements
revealed an intra-assay absolute methodological error
for HGF in breath condensate of 0?058 ngmlÿ1 that was
acceptable.
Contamination of breath condensate from saliva is a
possible technical problem. In this study the saliva trap
of the condensator was checked. It was macroscopically
clean in all cases. To further evaluate this factor, HGF
concentrations in saliva from thehealthycontrol subjects
weremeasured (mean 0?97 ngmlÿ1, range 0?17^2?27).No
correlation to condensate values were found (data not
shown). Thus the measured HGF in EBC in this study
FIG. 2. Individual HGFlevels in serum (a) and EBC (b) during the course oftreatment (day1and days 4^7) and atconvalescence (4^6
weeks).
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nia patients had signi¢cantly elevated concentrations in
EBC while the levels in other infectious diseases were
low, supporting the concept of a local production of
HGF. Furthermore, high EBC values in pneumonia per-
sistedduring the observation period of 4^6weekswhile
serum HGF levels decreased to normal. The changing
quotient between serum and breath condensate levels
of HGF during recovery shows that there is no correla-
tion between local and serum HGF levels. This discre-
pancy between local and systemic concentration of HGF
was also seen in a group of patients with meningitis and
indicates the presence of a local production and not a
leakage from plasma (13).
As mentioned, the patients with pneumonia in this
study were successfully treated based on clinical ¢nd-
ings, control chestX-rays and a decrease inHGF concen-
trations in serum. Why increased concentrations in
exhaled breath condensate persisted in this group is un-
explained in the present study. The length of increased
HGF production after pneumonia and its relation to
other lung diseases remain unknown. Along with thepossibility to use HGF in breath condensate for diagnos-
tic purposes, these results merit further studies. Local
application of HGF via inhalation, as an adjuvant treat-
ment in complicated pneumonia might also be consid-
ered in future studies.
In this study the presence and signi¢cantly higher
amounts of HGF in EBC in pneumonia have been shown.
A local production of HGF in the lungsmight participate
in therecoveryprocess after injuries causedby infection.
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